Arcus Biosciences, Inc.
Company Stats
- Market Cap
- $3.3B
- as of Sep 30, 2026
- Enterprise Value
- $3.2B
- Shares Outstanding
- 127.3M
- Free Float
- 63.1%
Income Statement
- Revenue
- $247.0M
- Operating Income
- -$386.0M
- Net Income
- -$353.0M
- EBITDA
- -$376.0M
- Revenue Growth, 3Y
- 30.2%
- FCF Margin, 3Y Avg
- -182.1%
- FCF Margin, Worst Year
- -282.1%
Cash Flow
- Free Cash Flow
- -$484.0M
- FCF Yield
- -14.7%
- Owner FCF Yield
- -16.5%
Balance Sheet
- Cash & Equivalents
- $222.0M
- Total Debt
- $100.0M
- Net Cash
- $122.0M
Returns & Capital
- SBC, 3Y Avg
- $69.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $247.0M | -$484.0M | -196.0% |
| FY2024 | $258.0M | -$176.0M | -68.2% |
| FY2023 | $117.0M | -$330.0M | -282.1% |
| FY2022 | $112.0M | $432.0M | 385.7% |
| FY2021 | $383.0M | -$282.0M | -73.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back